Articles tagged with Antibodies
Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its new variants. The nanobodies bind and neutralize the virus with extreme stability, making them promising agents to treat COVID-19.
A study found that antibodies produced to fight Covid-19 can trigger platelet activity, leading to fatal blood clots. Researchers developed a lab-based test to replicate this process, and suggest that existing medications may be able to inhibit platelet response.
Researchers developed a novel exosome-based treatment to deliver VEGF antibodies and suppress inflammation in ocular diseases. The therapy, rEXS-cL-aV, showed potent therapeutic efficacy in murine and nonhuman primate models.
Researchers have created an 'atlas' charting how antibodies attack the spike protein of SARS-CoV-2, identifying broadly responsive neutralizers and regions resistant to attack. The study highlights the importance of studying antibody responses for developing effective COVID-19 booster vaccines.
Researchers found that older people have lower antibody responses against COVID-19 variants, making them more susceptible to infection. Vaccination still appears effective in preventing severe illness, but promoting vaccinations is crucial to protect the community.
A rapid method to quantify antibodies against SARS-CoV-2 has been developed by scientists at Hokkaido University. The test is highly accurate, quick, and easy to perform, requiring only 20 minutes to complete.
Research suggests that fungi in the healthy gut can have a beneficial effect on health, while invasive forms may contribute to inflammatory bowel disease. Vaccines targeting specific proteins may help restore balance to the microbiome.
Researchers found that vaccination significantly increases neutralizing antibodies in saliva, reducing transmission risk. The study also shows the importance of receiving a second vaccine dose for maximum protection against evolving virus strains.
A new study reveals CoronaVac vaccine antibodies are less effective against the P.1 Brazil variant, raising concerns about vaccination program effectiveness and potential reinfection of previously infected individuals.
Researchers discovered the molecular mechanism behind vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but fatal blood clotting disorder. The findings will enable the development of rapid diagnostic tests and new strategies to prevent VITT, making vaccines safer.
Australian scientists found that COVID-19 survivors produced sustained antibodies but they were less effective against contemporary variants. The study suggests vaccination is more effective than the body's natural response and highlights the need for new vaccine designs to keep pace with emerging variants.
Researchers found that vaccines produced in chicken eggs induce an antibody response against a glycan called N-acetyllactosamine (LacNAc), which is not typically targeted by the immune system. This unexpected finding may impact the effectiveness of flu vaccines grown in eggs.
A study with healthcare workers found that most individuals retain anti-Spike antibodies for at least one year after infection, suggesting a long-lasting immune response. Vaccine-generated immunity is also expected to be long-lasting, according to the research.
A new Finnish study found that healthcare workers who received two doses of the Pfizer-BioNTech vaccine had strong antibody responses to SARS-CoV-2, with similar effectiveness against the alpha variant as the original virus. The immune response was weaker against the beta variant, but still provided relatively good protection.
Immunologists at McMaster University have identified a 'spider web' mechanism that traps pathogens like influenza and SARS-CoV-2 in neutrophils, creating a sticky tangle to kill viruses. This discovery could lead to new aerosol and nasal spray vaccine technologies to prevent infections before they spread.
Researchers at Tel-Aviv University have developed a targeted delivery system for RNA-based drugs that selectively targets diseased cells without harming healthy ones. The breakthrough has potential implications for various diseases, including blood cancers and inflammatory conditions.
A Duke-led team identified how multiple mutations on the SARS-CoV-2 spike protein create variants that are more transmissible and resistant to antibodies. The researchers found that different variant spikes use distinct mechanisms to achieve this, raising concerns about the effectiveness of current vaccines.
Researchers identified six antibody characteristics that protect pregnant women from placental malaria infections, which could be used to identify women at risk and develop new therapies. The study found that these antibodies help prevent malaria parasites from binding to placental cells and destroying infected blood cells.
A new tablet-sized device can detect multiple COVID-19 antibodies and biomarkers simultaneously, distinguishing between SARS-CoV-2 and four other coronaviruses with 100% accuracy. The test also shows promise in predicting COVID-19 case severity and immunity against variants.
Researchers at TUM created a low-cost, automated rapid test for detecting SARS-CoV-2 antibodies with high sensitivity and specificity. The test can determine antibody concentrations and has the potential to answer questions about corona immunity, vaccinations, and disease progression.
Researchers at NYU Langone Health have developed an antibody therapy that rescues mice from a lethal muscle-weakening disease by targeting another protein in the same signaling pathway. The treatment reverses disease relapse in adult mice, offering new hope for humans with congenital myasthenia.
A new study suggests that people who had COVID-19 need only one vaccine dose for protection and that boosters could be necessary for everyone in the future. The Pfizer-BioNTech and Moderna vaccines triggered antibody levels similar to those seen after mild COVID-19 infections with one dose.
An analysis of antibodies from over 8,000 undiagnosed adults found that nearly 5% of the US population harbored SARS-CoV-2 antibodies. The highest positivity rates were among African Americans and young urban dwellers.
Researchers developed two groups of molecules that effectively inhibit SARS-CoV-2 variants, bypassing mutations and disabling viral entry. The nanobodies recognize a conserved region of the receptor binding domain, blocking viral entry even when human antibodies cannot.
A new study published in Cell journal suggests that COVID-19 antibodies lack the ability to enhance disease in animals. The research used mice and monkeys to test human antibodies, finding that they exert their defensive powers against SARS-CoV-2 infection, not exacerbating it.
Researchers analyzed 24,000 blood samples and multiple antibody testing platforms to discover SARS-CoV-2 infections in five states earlier than reported. The findings expand on previous studies suggesting the virus was present in the US as early as December 2019.
Researchers found that a third vaccine dose increased antibody levels against SARS-CoV-2 in transplant recipients more than the standard two-dose regimen. The study suggests booster doses should be investigated for those who are immunocompromised to determine if they can receive COVID-19 vaccines as standard clinical practice.
A third dose of COVID-19 vaccine significantly increased antibody levels in organ transplant recipients who had a suboptimal response to standard vaccination. The study found that booster doses may be necessary for these patients, similar to hepatitis B and influenza vaccinations.
The study found that vaccinated individuals have lower antibody levels targeting the Delta variant compared to previously circulating variants. Booster doses and second vaccinations are recommended to ensure high protection against new variants.
Researchers found that prior COVID-19 infections reduced the risk of reinfection by 85% for care home residents and 60% for staff within a four-month period. The study, published in Lancet Healthy Longevity, used antibody testing to determine previous infection status.
Researchers at the University of Turku discovered a novel antibody treatment that reactivates the immune defense system in patients with advanced-stage cancer. The treatment activates killer T cells and lowers the suppressive potential of macrophages, leading to increased inflammation and white blood cell activity.
Researchers created high-resolution maps of the virus using cryogenic electron microscopy and custom software. The 3D image revealed that an antibody binding site on CPV significantly overlapped its receptor binding site, allowing antibodies to block virus attachment and neutralize infection.
Researchers discovered that antibody-secreting cells are formed in lung tissue after a respiratory infection, producing antibodies that fight microbes. These localized antibodies may play a key role in determining who becomes severely ill or experiences mild symptoms when infected.
A study found that cancer patients had lower SARS-CoV-2 antibody levels compared to healthcare workers. Health care workers in Japan had higher SARS-CoV-2 antibody levels, indicating a possible immune response to the virus.
A new study by Brigham and Women's Hospital uses an ultrasensitive test to detect circulating antigen in vaccinated individuals, showing a strong immune response. The test found evidence of low viral protein levels followed by antibody production and clearance of proteins from the blood.
Researchers found that people who had mild COVID-19 developed antibody-producing cells that can last a lifetime. These cells will continue to produce antibodies against the virus even after infection has resolved.
Researchers have developed novel immune checkpoint proteins that can combat autoimmune diseases and immunosuppression in cancer patients. These proteins, which include recombinant proteins and antibodies, show promise in animal models of autoimmune disease and inhibit tumor growth in cancer patients.
A large cohort study reveals that despite impaired immunity, dialysis patients maintain SARS-CoV-2 antibody levels for at least 6 months following infection. The researchers found no indication that subgroups with impaired immunity had a shorter-lived humoral response compared to healthy individuals.
Australian researchers have identified an immune response associated with protection from COVID-19, enabling the measurement of neutralising antibody levels as a proxy for immune protection. The discovery may lead to annual vaccine boosters and more efficient vaccine development.
Researchers at the Lundquist Institute have discovered an antibody that can protect against mucormycosis, a deadly fungal infection with a high mortality rate. The humanized monoclonal antibodies are being manufactured by Vitalex Biosciences and aim to improve treatment outcomes for patients with COVID-19.
Researchers found epigenetic modifications driven by DNMT3A protein determine B cell fate, with implications for understanding diseases linked to B cells' dysregulation. Chronic lymphomic leukemia (CLL) risk arises when these modifications are lost.
A new study found that immunocompromised pediatric patients showed significant T-cell activity and humoral immunity against SARS-CoV-2. The research suggests that vaccination may still be beneficial for this population, particularly those with antibody deficiency disorders. Further studies are needed to confirm these findings.
The study evaluates the validity of diagnostic criteria for anti-NMDA receptor encephalitis in children, revealing age-dependent symptom patterns. The sensitivity and specificity of the criteria were found to be high, with notable differences in presentation between pediatric and adult patients.
Researchers analyzed blood samples from 41 COVID-19 patients to understand which antibodies best combat the virus. The study found that antibody isotypes binding to the S protein were highly specific and correlated with virus neutralizing activity.
A study published in JAMA found that two doses of a COVID-19 vaccine provide some protection for people with solid organ transplants, but not enough to dispense with masks and physical distancing. Immunocompromised patients should continue to practice strict COVID-19 safety measures after vaccination.
Researchers developed nanosized cargo packages that can deliver water-soluble proteins into cancer cells while keeping them intact. The 'nanobrushes' use polymer strands with antibodies on the outside and protected proteins within.
Researchers discovered a new disease that prevents antibody formation, treating it with a bone marrow transplant from a sibling donor. The study found that the genetic mutation responsible for PU.MA affects B cell development and chromatin accessibility.
A team of researchers at the University of Texas at Austin has discovered that most SARS-CoV-2 antibodies target areas outside the receptor-binding domain, neutralizing the virus in cell cultures. This finding provides a promising lead for designing next-generation vaccines against variants and future coronaviruses.
Researchers are exploring the potential of individual immunomes to provide unprecedented insight into health. By analyzing antibodies and T-cell receptors, scientists can identify patterns and develop a near-universal blood test. This could lead to targeted therapies for various conditions, revolutionizing personalized medicine.
Researchers have identified how natural human antibodies can block malaria parasites from entering red blood cells, potentially indicating the development of new protective therapies. This discovery opens up new avenues for developing antibody-based therapies for malaria.
A large-scale study found that people treated with infliximab had significantly lower antibody concentrations after a single dose of COVID-19 vaccine. However, the vaccine-triggered antibody responses rose significantly in those who had previously been infected with COVID-19 or received a second dose. The researchers recommend prioriti...
Australian researchers have identified neutralizing nanobodies that block the SARS-CoV-2 virus from entering cells, paving the way for alternative treatments. The discovery of a nanobody recognizing emerging global variants and original SARS virus suggests potential cross-protection against human coronaviruses.
Researchers found that SARS-CoV-2 infection induces polyfunctional antibodies capable of neutralizing the virus and activating immune cells to destroy infected cells. Asymptomatic individuals also have these antibodies, but with slightly weaker responses.
A longitudinal study of over 3,000 young Marines found that past COVID-19 infection does not completely protect against reinfection. Young people with previous infection can still catch the virus and transmit it to others.
A new study from the University of Pennsylvania School of Medicine suggests that individuals who have recovered from COVID-19 may only need one vaccine dose to produce a sufficient antibody response. In contrast, those who have not had COVID-19 require two doses to achieve strong levels of immunity.
A team of scientists developed a machine learning method that optimizes antibody properties, identifying potential candidates for therapeutic use. The new approach increased the candidate pool from thousands to millions, leading to improved drug efficacy and stability.
A new study found that a single dose of the Pfizer or Moderna mRNA vaccine can stimulate an immune response in people who have previously recovered from COVID-19. The vaccine's ability to generate antibodies and B cell responses was shown to be effective against the South African variant.
Researchers developed a new fluorescent probe, CDgB, that can selectively target the cell membranes of B lymphocytes over T lymphocytes. The probe works by exploiting differences in membrane structures between B and T cells, particularly phospholipid composition and cholesterol content.
A recent study has linked Interleukin-33 to immunity against Sars-CoV-2. The researchers found that memory T cells and high levels of antibodies persisted in recovered patients, suggesting a strong immune response. This discovery could pave the way for better understanding of Sars-CoV-2 immunity and potential therapies.
Researchers discovered the first full structure of the Nucleocapsid protein, finding that antibody binding sites remain consistent across many coronaviruses, including recent COVID-19 variants.